RhumbLine Advisers’s Aura Biosciences AURA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$433K Sell
64,720
-314
-0.5% -$1.8K ﹤0.01% 2705
2025
Q4
$354K Sell
65,034
-4,003
-6% -$23.8K ﹤0.01% 2875
2025
Q3
$427K Buy
69,037
+3,630
+6% +$23.7K ﹤0.01% 2800
2025
Q2
$409K Buy
65,407
+1,369
+2% +$8.01K ﹤0.01% 2805
2025
Q1
$375K Sell
64,038
-9,581
-13% -$72.5K ﹤0.01% 2764
2024
Q4
$605K Sell
73,619
-269
-0.4% -$2.53K ﹤0.01% 2543
2024
Q3
$658K Buy
73,888
+10,405
+16% +$89.2K ﹤0.01% 2523
2024
Q2
$480K Buy
63,483
+18,011
+40% +$132K ﹤0.01% 2709
2024
Q1
$357K Buy
45,472
+5,589
+14% +$46.3K ﹤0.01% 2882
2023
Q4
$353K Sell
39,883
-183
-0.5% -$1.55K ﹤0.01% 2871
2023
Q3
$359K Buy
40,066
+389
+1% +$4.18K ﹤0.01% 2826
2023
Q2
$490K Buy
39,677
+9,890
+33% +$106K ﹤0.01% 2701
2023
Q1
$276K Buy
29,787
+7,117
+31% +$73.9K ﹤0.01% 2642
2022
Q4
$238K Buy
22,670
+331
+1% +$4.21K ﹤0.01% 2743
2022
Q3
$405K Buy
22,339
+1,626
+8% +$24.6K ﹤0.01% 2593
2022
Q2
$294K Buy
+20,713
New +$343K ﹤0.01% 2764

Other funds holding AURA

RhumbLine Advisers's AURA Position: Q1 2026 in Review

RhumbLine Advisers reduced its Aura Biosciences (AURA) stake by 0.48% in Q1 2026, selling an estimated $1.8K and leaving 64,720 shares worth $433K. The position accounts for ﹤0.01% of the portfolio, ranked #2705.

RhumbLine Advisers first reported a position in AURA in Q2 2022 and has held it in 16 quarters since. The position peaked at $658K in Q3 2024. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

  • RhumbLine Advisers held 64,720 shares of Aura Biosciences worth $433K as of Q1 2026.
  • RhumbLine Advisers sold 314 Aura Biosciences shares in Q1 2026, an estimated $1.8K.
  • Aura Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2705 holding.
  • RhumbLine Advisers first reported a position in Aura Biosciences in Q2 2022 and has held it in 16 quarters since.
  • RhumbLine Advisers's Aura Biosciences position peaked at $658K in Q3 2024.
  • 126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.